PortfoliosLab logoPortfoliosLab logo
STRO vs. NVDA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

STRO vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sutro Biopharma, Inc. (STRO) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, STRO achieves a 108.90% return, which is significantly higher than NVDA's 7.77% return.


STRO

1D
-2.62%
1M
-20.57%
6M
61.67%
YTD
108.90%
1Y
198.40%
3Y*
-18.41%
5Y*
-32.33%
10Y*
ALL TIME*
-20.85%

NVDA

1D
2.93%
1M
3.04%
6M
5.16%
YTD
7.77%
1Y
15.71%
3Y*
62.93%
5Y*
59.52%
10Y*
64.62%
ALL TIME*
36.28%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$25.46B$26.13B$31.85B
$6.33M$8.37M$10.40M

STRO vs. NVDA - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
STRO
Sutro Biopharma, Inc.
108.90%-37.12%-57.11%-46.91%-45.70%-31.46%97.36%21.95%-40.34%
NVDA
NVIDIA Corporation
7.77%38.92%171.25%239.02%-50.26%125.48%122.30%76.94%-49.93%

Correlation

The correlation between STRO and NVDA is 0.10, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.10

Correlation (3Y)
Balances recent behavior with more history.

0.16

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.21

Correlation (All Time)
Calculated using the full available price history since Sep 27, 2018

0.24

The correlation between STRO and NVDA shifts across timeframes, from 0.10 (1 year) to 0.24 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

STRO:

$233.90M

NVDA:

$4.86T

EPS

STRO:

-$15.28

NVDA:

$6.53

PS Ratio

STRO:

2.44

NVDA:

19.35

Total Revenue (TTM)

STRO:

$99.61M

NVDA:

$253.49B

Gross Profit (TTM)

STRO:

$83.46M

NVDA:

$187.95B

EBITDA (TTM)

STRO:

-$105.17M

NVDA:

$192.76B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

STRO vs. NVDA — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

STRO
STRO Risk / Return Rank: 9191
Overall Rank
STRO Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
STRO Sortino Ratio Rank: 8989
Sortino Ratio Rank
STRO Omega Ratio Rank: 8787
Omega Ratio Rank
STRO Calmar Ratio Rank: 9494
Calmar Ratio Rank
STRO Martin Ratio Rank: 9191
Martin Ratio Rank

NVDA
NVDA Risk / Return Rank: 5656
Overall Rank
NVDA Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
NVDA Sortino Ratio Rank: 5353
Sortino Ratio Rank
NVDA Omega Ratio Rank: 5151
Omega Ratio Rank
NVDA Calmar Ratio Rank: 6060
Calmar Ratio Rank
NVDA Martin Ratio Rank: 5959
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

STRO vs. NVDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sutro Biopharma, Inc. (STRO) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


STRONVDADifference
Sharpe ratioReturn per unit of total volatility

+1.88

Sortino ratioReturn per unit of downside risk

+1.95

Omega ratioGain probability vs. loss probability

1.32

1.09

+0.24

Calmar ratioReturn relative to maximum drawdown

4.50

0.65

+3.85

Martin ratioReturn relative to average drawdown

10.46

1.32

+9.14

STRO vs. NVDA - Sharpe Ratio Comparison

The current STRO Sharpe Ratio is 2.24, which is higher than the NVDA Sharpe Ratio of 0.36. The chart below compares the historical Sharpe Ratios of STRO and NVDA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

STRO vs. NVDA - Drawdown Comparison

The maximum STRO drawdown since its inception was -98.10%, which is greater than NVDA's maximum drawdown of -89.72%. Use the drawdown chart below to compare losses from any high point for STRO and NVDA.


Loading charts...

Drawdown Indicators


STRONVDADifference

Max Drawdown

Largest peak-to-trough decline

-98.10%

-89.72%

-8.38%

Max Drawdown (1Y)

Largest decline over 1 year

-44.78%

-20.21%

-24.57%

Max Drawdown (3Y)

Largest decline over 3 years

-90.72%

-36.88%

-53.84%

Max Drawdown (5Y)

Largest decline over 5 years

-97.77%

-66.34%

-31.43%

Max Drawdown (10Y)

Largest decline over 10 years

-66.34%

Current Drawdown

Current decline from peak

-91.22%

-14.74%

-76.48%

Average Drawdown

Average peak-to-trough decline

-61.80%

-36.07%

-25.73%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.22%

9.90%

+9.32%

Volatility

STRO vs. NVDA - Volatility Comparison

Sutro Biopharma, Inc. (STRO) has a higher volatility of 18.26% compared to NVIDIA Corporation (NVDA) at 12.04%. This indicates that STRO's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


STRONVDADifference

Volatility (1M)

Calculated over the trailing 1-month period

18.26%

12.04%

+6.22%

Volatility (6M)

Calculated over the trailing 6-month period

59.56%

28.30%

+31.26%

Volatility (1Y)

Calculated over the trailing 1-year period

90.29%

36.41%

+53.88%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

88.71%

51.87%

+36.84%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

85.24%

49.95%

+35.29%

Dividends

STRO vs. NVDA - Dividend Comparison

STRO has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.14%.


PositionTTM20252024202320222021202020192018201720162015
NVDA
NVIDIA Corporation
0.14%0.02%0.03%0.03%0.11%0.05%0.12%0.27%0.46%0.29%0.45%1.20%
STRO
Sutro Biopharma, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

STRO vs. NVDA - Financials Comparison

This section allows you to compare key financial metrics between Sutro Biopharma, Inc. and NVIDIA Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


STRO and NVDA have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

STRO has higher volatility (18.26%) compared to NVDA (12.04%). In terms of maximum drawdown, STRO dropped -98.10% vs NVDA's -89.72%.

STRO currently has the higher Sharpe Ratio (2.24 vs 0.36), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for STRO and NVDA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer